Clinical Trial Update: Inclisiran (Leqvio®) in Patients With Atherosclerotic Vascular Disease and/or Heterozygous Familial Hypercholesterolemia Treated in Spain: the INSPIRE Study

View source ↗

Summary

Clinical trial update for Inclisiran (Leqvio) in patients with atherosclerotic vascular disease or heterozygous familial hypercholesterolemia in Spain (INSPIRE …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Vascular Disease
• Heterozygous Familial Hypercholesterolemia

Drugs mentioned

• LEQVIO (inclisiran)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Atherosclerotic Vascular Disease, Heterozygous Familial Hypercholesterolemia | Status: RECRUITING